Literature DB >> 8539309

Time course of the corticosteroid-dopaminergic interaction during metyrapone and dexamethasone administration.

S Lupien1, R Richter, S C Risch, A Mirow, J C Gillin, R L Hauger.   

Abstract

Recent studies performed with depressed patients and normal subjects suggest that corticosteroids may alter dopaminergic activity. We measured the time course of the interaction between corticosteroid and plasma homovanillic acid (HVA) levels in 10 young healthy subjects after the administration of 2 mg of dexamethasone in session 1 and after the administration of 4.5 g of metyrapone in session 2. Plasma levels of adrenocorticotropic hormone (ACTH), 11-desoxycortisol, cortisol, HVA, and prolactin (PRL) were measured at 08:00, 09:00, 12:00, 15:00, and 16:00 h on a baseline day and during both drug-administration sessions. Dexamethasone administration resulted in a significant decrease in plasma levels of ACTH, 11-desoxycortisol, and cortisol at all time points and to a significant decrease in PRL secretion in the early morning. Plasma HVA levels were unchanged after dexamethasone administration. Metyrapone administration resulted in a significant decrease in cortisol levels and a significant increase in ACTH and 11-desoxycortisol levels. Plasma HVA levels were significantly increased in the early morning, while PRL levels were unaltered. These results are discussed in relation to the neurochemical and behavioral changes associated with steroid administration and interpreted with regard to a possible association between HVA and PRL in the effects of corticosteroids on dopaminergic activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8539309     DOI: 10.1016/0165-1781(95)02646-e

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  1 in total

1.  Elevated prolactin responses to L-tryptophan infusion in medication-free depressed patients.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Margaret S Smith; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2003-05-01       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.